Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial

Jankovic, Joseph; Berkovich, Elijahu; Eyal, Eli; Tolosa, Eduardo

doi:10.1016/j.parkreldis.2014.02.024

Cited by 37 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although gait was not an outcome in the original study, results from a follow-up study suggested that PD patients on MAOB-I were less likely to develop FoG [79, 80] and had less increase of PIGD scores over a period of 36 weeks [81]. These findings were in line with earlier work showing marginally faster gait speed in PD subjects on MAOB-I compared to placebo [82].…”

Section: Other Antiparkinsonian Drugssupporting

confidence: 58%

Pharmacological treatment in Parkinson's disease: Effects on gait

Smulders

Dale

Carlson‐Kuhta

et al. 2016

Parkinsonism & Related Disorders

139

129

View full text Add to dashboard Cite

Gait impairments are a hallmark of Parkinson's disease (PD), both as an early symptom and an important cause of disability later in the disease course. Although levodopa has been shown to improve gait speed and step length, the effect of dopamine replacement therapy on other aspects of gait is less well understood. In fact, falls are not reduced and some aspects of postural instability during gait are unresponsive to dopaminergic treatment. Moreover, many medications, other than dopaminergic agents, can benefit or impair gait in people with PD. We review the effects of pharmacological interventions used in PD on gait, discriminating, whenever possible, among effects on four components of everyday mobility: straight walking, gait initiation, turning, gait adaptability. Additionally, we summarize the effects on freezing of gait. There is substantial evidence for improvement of spatial characteristics of simple, straight-ahead gait with levodopa and levodopa-enhancing drugs. Recent work suggests that drugs aiming to enhance the acetylcholine system might improve gait stability measures. There is a lack of well-designed studies to evaluate effects on more complex, but highly relevant walking abilities such as turning and flexible adjustments of gait. Finally, paucity in the literature exists on detrimental effects of drugs used in PD that are known to worsen gait and postural stability in the elderly population.

show abstract

Section: Other Antiparkinsonian Drugssupporting

confidence: 58%

Pharmacological treatment in Parkinson's disease: Effects on gait

Smulders

Dale

Carlson‐Kuhta

et al. 2016

Parkinsonism & Related Disorders

139

129

View full text Add to dashboard Cite

show abstract

“…As presented in Figure S1, 110 publications involving 24,864 participants were finally included in the present study after screening 1,154 publications according to the inclusion criteria1315161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111…”

Section: Resultsmentioning

confidence: 99%

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Zhuo

Zhu

Jiang³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a long term disorder affects the central nervous system and we aim to determine the relative efficacy of the current available drugs used in PD. Firstly, we performed a systematic review in current literature and eligible studies were retrieved from online databases, relevant data were extracted. Efficacy of these medications was assessed by different Unified Parkinson’s Disease Rating Scales (UPDRS). Mean difference (MD) and odds ratio (OR) were produced by pairwise or network meta-analysis (NMA). Finally, we performed a cluster analysis for the included medications with respect to their surface under the cumulative ranking curve (SUCRA). Pairwise meta-analysis suggests that selegiline had a higher ranking in UPDRS II, UPDRS III and UPDRS total than bromocriptine and levodopa. Selegiline was more tolerable than bromocriptine (OR = 0.62, CI: 0.39 to 0.98) and pramipexole was less tolerable than levodopa (OR = 1.43, CI = 1.00 to 2.04). Results of NMA indicate that patients with levodopa, pramipexole, ropinirole and selegiline exhibited a significantly improved UPDRS III than those with lazabemide. To sum up, levodopa, selegiline, ropinirole and rotigotine were recommended for PD patients as they appeared relatively high efficacy and tolerability.

show abstract

“…To our knowledge, there are no empiric data assessing the effect of MAOB‐Is on risk of falls. With regard to gait deterioration, post‐hoc analysis of data from a long‐term study suggest that rasagiline is associated with less deterioration of gait compared with placebo, and long‐term data suggest that selegiline is associated with greater dyskinesia but less FoG . With regard to hallucinations, several lines of evidence demonstrate that selegiline is associated with an increased risk of hallucinations; however, the risk of hallucinations with long‐term rasagiline treatment is unknown.…”

mentioning

confidence: 99%

Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type‐B inhibitor: A Cross‐Sectional, Cohort Study

et al. 2015

View full text Add to dashboard Cite

Study ObjectiveTo evaluate the long‐term risk of developing cognitive symptoms (e.g., dementia, hallucinations), dyskinesia, falls, and freezing of gait (FoG) in patients with Parkinson's disease (PD) who received monoamine oxidase type B inhibitors (MAOB‐Is) compared with patients who had never received MAOB‐Is.DesignRetrospective, cross‐sectional, cohort study.SettingAcademic movement disorders clinic.PatientsOne hundred eighty‐one patients with idiopathic PD who were receiving MAOB‐I therapy on a long‐term basis for a minimum of 1 year (MAOB‐I current‐user cohort) and 121 patients with idiopathic PD who had never received MAOB‐I therapy (MAOB‐I never‐user cohort [control group]) between January 1, 1996, and November 30, 2011.Measurements and Main ResultsThe five study outcome variables were dementia, dyskinesia, falls, FoG, and hallucinations. Baseline and outcome data were collected from medical records. Patients in the MAOB‐I current‐user group were included only if absence of the specified outcomes was documented at baseline. Adjusted multiple logistic regression analyses were performed to calculate the odds ratios (ORs) for MAOB‐I use versus never use on clinical outcomes. MAOB‐I treatment was associated with a 44.7% reduced risk of dyskinesia (adjusted OR 0.553, 95% confidence interval 0.314–0.976, p=0.041), with the greatest risk reduction observed after 2 years of treatment. No significant association was noted with MAOB‐I use and development of dementia, falls, FoG, or hallucinations.ConclusionLong‐term use of MAOB‐I therapy was associated with reduced risk of dyskinesia in patients with PD.

show abstract

Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial

Cited by 37 publications

References 11 publications

Pharmacological treatment in Parkinson's disease: Effects on gait

Pharmacological treatment in Parkinson's disease: Effects on gait

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type‐B inhibitor: A Cross‐Sectional, Cohort Study

Contact Info

Product

Resources

About